About Omniose
Omniose is an early-stage biotechnology company developing polysaccharide conjugate vaccines against serious bacterial threats using its own bioconjugation platform. The platform precisely attaches almost any bacterial polysaccharide (sugar) antigen to engineered carrier proteins, using enzymes inside a single E. coli cell. The name Omniose means “all sugars.” It has used the platform to develop vaccine candidates against Group B Streptococcus, Klebsiella pneumoniae, and Streptococcus pneumoniae, supported by $14.7 million in grants from the US NIAID. Much of this work targets multidrug-resistant bacteria. Its main partner has been AstraZeneca, first through an exclusive research collaboration and now as its owner. Omniose is now a wholly owned subsidiary within AstraZeneca’s Infectious Disease Unit, and its platform supports AstraZeneca’s preclinical vaccine programs. Founded in 2016, the company is headquartered in St. Louis, Missouri, United States.